OLN241220P70000
- 27.40
- 0.000.00%
Olin Newsroom
Those Who Invested in Olin (NYSE:OLN) Five Years Ago Are up 177%
Olin Biotech (688319.SH): received a government subsidy of 2.24 million yuan.
Glonghui November 28丨 Olin Bioscience (688319.SH) announced that its wholly-owned subsidiary Chongqing Yuanlun Biological Technology Co., Ltd. recently received government subsidies totaling 2.24 million yuan, with 2.24 million yuan related to income and 0 yuan related to assets.
When Should You Buy Olin Corporation (NYSE:OLN)?
Are Options Traders Betting on a Big Move in Olin (OLN) Stock?
Olin Announces Leadership Transition With New CLO Appointment
Olin's New Receivables Purchase Agreement and Financial Shift
Express News | Olin Corp - Agreement Has Three-Year Term
Express News | Olin Corp - Enters Into $500 Million Receivables Purchase Agreement
US Manufacturing Index Rises To 43, Highest Since 2020
Olin To Go Ex-Dividend On November 14th, 2024 With 0.2 USD Dividend Per Share
Olin Corporation (NYSE:OLN) Will Pay A US$0.20 Dividend In Three Days
FBI Firearm Background Checks Track Higher Ahead of the U.S. Election
Piper Sandler Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $51
Olin Is Maintained at Market Perform by BMO Capital
Olin Biology (688319.SH): The proposed additional fundraising will not exceed 0.3 billion yuan.
Great Wisdom News on October 29th: Olin Biology (688319.SH) announced that the total amount of funds raised by the company in this stock issuance shall not exceed 175.2929 million yuan (including this amount), not exceeding 0.3 billion yuan and not exceeding 20% of the net assets at the end of the latest year. The net proceeds of the funds raised after deducting the relevant issuance expenses are intended to be invested in the following project: Vaccine research and production base technology renovation project.
Morgan Stanley Maintains Olin(OLN.US) With Sell Rating, Maintains Target Price $41
Express News | Olin Corp : BMO Cuts Target Price to $47 From $50
RBC Capital Maintains Olin(OLN.US) With Buy Rating, Cuts Target Price to $48
Olin Biology (688319.SH): The net income in the first three quarters was 4.0259 million yuan, a year-on-year decrease of 86.71%.
On October 29th, Olin Biology (688319.SH) released the third quarter report for 2024, with a company's revenue of 0.387 billion yuan for the first three quarters, a year-on-year increase of 9.75%; net income attributable to shareholders of the listed company was 4.0259 million yuan, a year-on-year decrease of 86.71%; basic earnings per share was 0.0099 yuan.
Evaluating Olin: Insights From 6 Financial Analysts